Diminished neo-antigen response to keyhole limpet hemocyanin (KLH) vaccines in patients after treatment with chemotherapy or hematopoietic cell transplantation. 2005

Jeffrey S Miller, and Julie Curtsinger, and Melinda Berthold, and Kirsten Malvey, and Robin L Bliss, and Chap T Le, and Susan K Fautsch, and Arkadiusz Z Dudek, and Bruce R Blazar, and Angela Panoskaltsis-Mortari
Divisions of Medical and Pediatric Hematology-Oncology and Transplantation, The Blood and Marrow Transplant Program, Department of Biostatistics, and The University of Minnesota Cancer Center, MN 55455, USA. mille011@umn.edu

Relapse is the most common cause of treatment failure for advanced cancer, even those treated with autologous hematopoietic cell transplantation (HCT). Effective tumor-specific immunotherapy may decrease relapse, however, this will fail if the immune system is unable to respond. We developed a strategy to test immune responses with a single injection of the bona fide neo-antigen KLH. The model was first tested in 37 normal volunteers using three KLH vaccines: Intracel KLH, Biosyn KLH, and Biosyn KLH + adjuvant. Despite finding the immunogenic epitope conserved in both products, intact Intracel KLH induced a better response compared to a purified 350/390 kDA subunit of KLH contained in the Biosyn KLH product. Addition of a synthetic oil adjuvant (Montanide ISA51) restored the response to a single injection of Biosyn KLH. A quantitative readout measured by a KLH-specific cellular and humoral response with isotype switching 1 month after KLH vaccination was established. To test the integrity of the adaptive immune response in cancer patients, we vaccinated 14 patients post-HCT and 19 patients with advanced cancer with KLH vaccines that elicited a 100% response rate in normal volunteers. In marked contrast to normal subjects, both responses were significantly impaired up to 16 months after autologous HCT with an intermediate response in advanced cancer patients. KLH vaccines are safe and require only a single injection to test neo-antigen responses providing an optimal platform for definitive testing of strategies to improve diminished immune recovery after chemotherapy or post-HCT.

UI MeSH Term Description Entries
D007136 Immunoglobulins Multi-subunit proteins which function in IMMUNITY. They are produced by B LYMPHOCYTES from the IMMUNOGLOBULIN GENES. They are comprised of two heavy (IMMUNOGLOBULIN HEAVY CHAINS) and two light chains (IMMUNOGLOBULIN LIGHT CHAINS) with additional ancillary polypeptide chains depending on their isoforms. The variety of isoforms include monomeric or polymeric forms, and transmembrane forms (B-CELL ANTIGEN RECEPTORS) or secreted forms (ANTIBODIES). They are divided by the amino acid sequence of their heavy chains into five classes (IMMUNOGLOBULIN A; IMMUNOGLOBULIN D; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M) and various subclasses. Globulins, Immune,Immune Globulin,Immune Globulins,Immunoglobulin,Globulin, Immune
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D012008 Recurrence The return of a sign, symptom, or disease after a remission. Recrudescence,Relapse,Recrudescences,Recurrences,Relapses
D006433 Hemocyanins Metalloproteins that function as oxygen transport proteins in the HEMOLYMPH of MOLLUSKS and ARTHROPODS. They are characterized by two copper atoms, coordinated with HISTIDINE residues, that reversibly bind a single oxygen molecule; they do not contain HEME groups. Hemocyanin,alpha-Haemocyanin,alpha-Hemocyanin,alpha-Hemocyanins,alpha Haemocyanin,alpha Hemocyanin,alpha Hemocyanins
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D015415 Biomarkers Measurable and quantifiable biological parameters (e.g., specific enzyme concentration, specific hormone concentration, specific gene phenotype distribution in a population, presence of biological substances) which serve as indices for health- and physiology-related assessments, such as disease risk, psychiatric disorders, ENVIRONMENTAL EXPOSURE and its effects, disease diagnosis; METABOLIC PROCESSES; SUBSTANCE ABUSE; PREGNANCY; cell line development; EPIDEMIOLOGIC STUDIES; etc. Biochemical Markers,Biological Markers,Biomarker,Clinical Markers,Immunologic Markers,Laboratory Markers,Markers, Biochemical,Markers, Biological,Markers, Clinical,Markers, Immunologic,Markers, Laboratory,Markers, Serum,Markers, Surrogate,Markers, Viral,Serum Markers,Surrogate Markers,Viral Markers,Biochemical Marker,Biologic Marker,Biologic Markers,Clinical Marker,Immune Marker,Immune Markers,Immunologic Marker,Laboratory Marker,Marker, Biochemical,Marker, Biological,Marker, Clinical,Marker, Immunologic,Marker, Laboratory,Marker, Serum,Marker, Surrogate,Serum Marker,Surrogate End Point,Surrogate End Points,Surrogate Endpoint,Surrogate Endpoints,Surrogate Marker,Viral Marker,Biological Marker,End Point, Surrogate,End Points, Surrogate,Endpoint, Surrogate,Endpoints, Surrogate,Marker, Biologic,Marker, Immune,Marker, Viral,Markers, Biologic,Markers, Immune
D015496 CD4-Positive T-Lymphocytes A critical subpopulation of T-lymphocytes involved in the induction of most immunological functions. The HIV virus has selective tropism for the T4 cell which expresses the CD4 phenotypic marker, a receptor for HIV. In fact, the key element in the profound immunosuppression seen in HIV infection is the depletion of this subset of T-lymphocytes. T4 Cells,T4 Lymphocytes,CD4-Positive Lymphocytes,CD4 Positive T Lymphocytes,CD4-Positive Lymphocyte,CD4-Positive T-Lymphocyte,Lymphocyte, CD4-Positive,Lymphocytes, CD4-Positive,T-Lymphocyte, CD4-Positive,T-Lymphocytes, CD4-Positive,T4 Cell,T4 Lymphocyte
D018380 Hematopoietic Stem Cell Transplantation Transfer of HEMATOPOIETIC STEM CELLS from BONE MARROW or BLOOD between individuals within the same species (TRANSPLANTATION, HOMOLOGOUS) or transfer within the same individual (TRANSPLANTATION, AUTOLOGOUS). Hematopoietic stem cell transplantation has been used as an alternative to BONE MARROW TRANSPLANTATION in the treatment of a variety of neoplasms. Stem Cell Transplantation, Hematopoietic,Transplantation, Hematopoietic Stem Cell
D019496 Cancer Vaccines Vaccines or candidate vaccines designed to prevent or treat cancer. Vaccines are produced using the patient's own whole tumor cells as the source of antigens, or using tumor-specific antigens, often recombinantly produced. Cancer Vaccine,Neoplasm Vaccines,Tumor Vaccine,Tumor Vaccines,Vaccines, Cancer,Vaccines, Neoplasm,Vaccines, Tumor,Vaccine, Cancer,Vaccine, Tumor

Related Publications

Jeffrey S Miller, and Julie Curtsinger, and Melinda Berthold, and Kirsten Malvey, and Robin L Bliss, and Chap T Le, and Susan K Fautsch, and Arkadiusz Z Dudek, and Bruce R Blazar, and Angela Panoskaltsis-Mortari
January 1996, Anticancer research,
Jeffrey S Miller, and Julie Curtsinger, and Melinda Berthold, and Kirsten Malvey, and Robin L Bliss, and Chap T Le, and Susan K Fautsch, and Arkadiusz Z Dudek, and Bruce R Blazar, and Angela Panoskaltsis-Mortari
October 2001, Journal of cancer research and clinical oncology,
Jeffrey S Miller, and Julie Curtsinger, and Melinda Berthold, and Kirsten Malvey, and Robin L Bliss, and Chap T Le, and Susan K Fautsch, and Arkadiusz Z Dudek, and Bruce R Blazar, and Angela Panoskaltsis-Mortari
March 1993, The Journal of urology,
Jeffrey S Miller, and Julie Curtsinger, and Melinda Berthold, and Kirsten Malvey, and Robin L Bliss, and Chap T Le, and Susan K Fautsch, and Arkadiusz Z Dudek, and Bruce R Blazar, and Angela Panoskaltsis-Mortari
January 1982, International archives of allergy and applied immunology,
Jeffrey S Miller, and Julie Curtsinger, and Melinda Berthold, and Kirsten Malvey, and Robin L Bliss, and Chap T Le, and Susan K Fautsch, and Arkadiusz Z Dudek, and Bruce R Blazar, and Angela Panoskaltsis-Mortari
August 2002, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society,
Jeffrey S Miller, and Julie Curtsinger, and Melinda Berthold, and Kirsten Malvey, and Robin L Bliss, and Chap T Le, and Susan K Fautsch, and Arkadiusz Z Dudek, and Bruce R Blazar, and Angela Panoskaltsis-Mortari
September 1995, Cancer immunology, immunotherapy : CII,
Jeffrey S Miller, and Julie Curtsinger, and Melinda Berthold, and Kirsten Malvey, and Robin L Bliss, and Chap T Le, and Susan K Fautsch, and Arkadiusz Z Dudek, and Bruce R Blazar, and Angela Panoskaltsis-Mortari
January 1991, Die Naturwissenschaften,
Jeffrey S Miller, and Julie Curtsinger, and Melinda Berthold, and Kirsten Malvey, and Robin L Bliss, and Chap T Le, and Susan K Fautsch, and Arkadiusz Z Dudek, and Bruce R Blazar, and Angela Panoskaltsis-Mortari
March 2017, Scientific reports,
Jeffrey S Miller, and Julie Curtsinger, and Melinda Berthold, and Kirsten Malvey, and Robin L Bliss, and Chap T Le, and Susan K Fautsch, and Arkadiusz Z Dudek, and Bruce R Blazar, and Angela Panoskaltsis-Mortari
October 2014, Journal of immunotoxicology,
Jeffrey S Miller, and Julie Curtsinger, and Melinda Berthold, and Kirsten Malvey, and Robin L Bliss, and Chap T Le, and Susan K Fautsch, and Arkadiusz Z Dudek, and Bruce R Blazar, and Angela Panoskaltsis-Mortari
October 2001, Journal of cancer research and clinical oncology,
Copied contents to your clipboard!